Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.090
+0.030 (0.98%)
Nov 21, 2024, 11:34 AM EST - Market open
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $54.27M in the quarter ending September 30, 2024, with 12.31% growth. This brings the company's revenue in the last twelve months to $187.36M, up 22.72% year-over-year. In the year 2023, Xeris Biopharma Holdings had annual revenue of $163.91M with 48.68% growth.
Revenue (ttm)
$187.36M
Revenue Growth
+22.72%
P/S Ratio
2.35
Revenue / Employee
$496,979
Employees
377
Market Cap
460.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Esperion Therapeutics | 295.45M |
SIGA Technologies | 173.73M |
Pacific Biosciences of California | 173.15M |
Arcturus Therapeutics Holdings | 160.40M |
National Research | 144.16M |
Quanterix | 129.33M |
Aquestive Therapeutics | 58.90M |
Foghorn Therapeutics | 25.52M |
XERS News
- 12 days ago - Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Xeris Biopharma Reports Third Quarter 2024 Financial Results - Business Wire
- 21 days ago - Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 - Business Wire
- 26 days ago - Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive - Seeking Alpha
- 5 weeks ago - Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips + - Seeking Alpha
- 6 weeks ago - Xeris Biopharma: Time For A Reassessment - Seeking Alpha
- 6 weeks ago - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Xeris to Participate in Upcoming Investor Conferences - Business Wire